EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-component vaccine comprising at least three antigens to protect against disease cased by Haemophilus influenzae



Multi-component vaccine comprising at least three antigens to protect against disease cased by Haemophilus influenzae



Official Gazette of the United States Patent & Trademark Office Patents 1254(5), Jan 29



A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least three different antigens of Haemophilus influenzae, two of which are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus influenzae comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The Haemophilus vaccine may be combined with DTP component vaccines, which may contain inactivated poliovirus, including type 1, type 2 and/or type 3, and/or a conjugate of a capsular polysaccharide of Haemophilus influenzae and tetanus or diphtheria toxoid, including PRP-T, to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.

(PDF 0-2 workdays service: $29.90)

Accession: 035349076

Download citation: RISBibTeXText



Related references

Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis. Official Gazette of the United States Patent & Trademark Office Patents 1258(3), May 21, 2002

Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatric Infectious Disease Journal 11(8): 610-613, 1992

Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae Study Group. Clinical Infectious Diseases 22(6): 1069-1076, 1996

Methylase activities from Haemophilus influenzae that protect Haemophilus parainfluenzae transforming deoxyribonucleic acid from inactivation by Haemophilus influenzae endonuclease R. Journal of Bacteriology 123(1): 287-293, 1975

Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 27(2): 167-176, 1999

Invasive Haemophilus influenzae disease in a rural area since the introduction of the Haemophilus influenzae type B vaccine. Journal of Investigative Medicine 50(1): 127A, January, 2002

Methylase activities from haemophilus influenzae that protect haemophilus parainfluenzae transforming dna from inactivation by haemophilus influenzae endo nuclease r. Journal of Bacteriology 123(1): 287-293, 1975

Immunization with oligosaccharide conjugate haemophilus influenzae type b hboc vaccine on a large health maintenance organization population extended follow up and impact on haemophilus influenzae disease epidemiology. Pediatric Infectious Disease Journal 11(8): 610-613, 1992

Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. Journal of Pediatrics 163(1 Suppl): S4-S7, 2013

Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. Pediatric Infectious Disease Journal 8(5): 297-302, 1989

Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatric Infectious Disease Journal 14(11): 978-981, 1995

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group. Lancet 338(8764): 395-398, 1991

Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatric Infectious Disease Journal 20(3): 300-305, 2001

The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease?. Pediatric Infectious Disease Journal 17(9 Suppl): S123-S125, 1998